[go: up one dir, main page]

BRPI0813553A2 - composições farmacêuticas e métodos para tratamento de distúrbios do olho seco - Google Patents

composições farmacêuticas e métodos para tratamento de distúrbios do olho seco

Info

Publication number
BRPI0813553A2
BRPI0813553A2 BRPI0813553A BRPI0813553A BRPI0813553A2 BR PI0813553 A2 BRPI0813553 A2 BR PI0813553A2 BR PI0813553 A BRPI0813553 A BR PI0813553A BR PI0813553 A BRPI0813553 A BR PI0813553A BR PI0813553 A2 BRPI0813553 A2 BR PI0813553A2
Authority
BR
Brazil
Prior art keywords
methods
pharmaceutical compositions
dry eye
eye disorders
treating dry
Prior art date
Application number
BRPI0813553A
Other languages
English (en)
Inventor
Rodney Beals Channing
Woldemussie Elizabeth
John Gukasyan Hovhannes
Ma Jingwen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0813553A2 publication Critical patent/BRPI0813553A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0813553A 2007-07-11 2008-07-04 composições farmacêuticas e métodos para tratamento de distúrbios do olho seco BRPI0813553A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94921607P 2007-07-11 2007-07-11
US6003208P 2008-06-09 2008-06-09
PCT/IB2008/001819 WO2009007839A1 (en) 2007-07-11 2008-07-04 Pharmaceutical compositions and methods of treating dry eye disorders

Publications (1)

Publication Number Publication Date
BRPI0813553A2 true BRPI0813553A2 (pt) 2017-05-09

Family

ID=39925011

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813553A BRPI0813553A2 (pt) 2007-07-11 2008-07-04 composições farmacêuticas e métodos para tratamento de distúrbios do olho seco

Country Status (15)

Country Link
US (2) US8541426B2 (pt)
EP (1) EP2175858B1 (pt)
JP (2) JP5649270B2 (pt)
KR (2) KR101258316B1 (pt)
CN (1) CN101743009A (pt)
AR (1) AR067495A1 (pt)
AU (1) AU2008273804B2 (pt)
BR (1) BRPI0813553A2 (pt)
CA (1) CA2691914C (pt)
ES (1) ES2523303T3 (pt)
NZ (1) NZ582188A (pt)
RU (1) RU2445098C2 (pt)
TW (1) TWI364281B (pt)
WO (1) WO2009007839A1 (pt)
ZA (1) ZA201000991B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG137989A1 (en) 2005-06-08 2008-01-28 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2343298B9 (en) 2005-12-13 2020-05-06 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
NZ582188A (en) * 2007-07-11 2012-03-30 Pfizer Pharmaceutical compositions and methods of treating dry eye disorders
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
CA2759026C (en) 2009-04-20 2019-01-15 Auspex Pharmaceuticals, Inc. Piperidine inhibitors of janus kinase 3
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
HRP20192203T1 (hr) 2009-05-22 2020-03-06 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori
MX337849B (es) * 2009-07-28 2016-03-09 Rigel Pharmaceuticals Inc Composiciones y metodos para inhibicion de la via jak.
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
MY161078A (en) 2010-05-21 2017-04-14 Incyte Holdings Corp Topical formulation for a jak inhibitor
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
SG193245A1 (en) * 2011-04-08 2013-10-30 Pfizer Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US10973680B2 (en) 2012-01-04 2021-04-13 Sight Sciences, Inc. Controller for dry eye treatment systems
US9510972B2 (en) 2012-01-04 2016-12-06 Sight Sciences, Inc. Dry eye treatment systems
US9724230B2 (en) 2012-01-04 2017-08-08 Sight Sciences, Inc. Dry eye treatment apparatus and methods
US11285040B2 (en) 2012-01-04 2022-03-29 Sight Sciences, Inc. Combination treatment systems
TWI702057B (zh) 2012-11-15 2020-08-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
CN103073552B (zh) * 2013-02-05 2015-08-12 华润赛科药业有限责任公司 一种无定型枸橼酸托法替尼的制备方法
ES2900492T3 (es) 2013-03-06 2022-03-17 Incyte Holdings Corp Procesos y productos intermedios para elaborar un inhibidor de JAK
CN104341422A (zh) * 2013-07-26 2015-02-11 重庆医药工业研究院有限责任公司 托菲替尼的中间体及其制备方法
RS60469B1 (sr) 2013-08-07 2020-07-31 Incyte Corp Dozni oblici sa produženim oslobađanjem za jak1 inhibitor
CN104447751A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 一种托法替尼化合物
CN104447752A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 一种托法替尼水合物及其制备方法
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2016064078A1 (ko) * 2014-10-22 2016-04-28 주식회사 지트리비앤티 티모신 베타 4를 함유하는 조성물 및 이를 포함하는 약학적 제형
CN104857287B (zh) * 2015-04-21 2021-05-11 湖南中医药大学 一种治疗干眼症的中药滴眼液及其制备方法
US9867868B2 (en) * 2015-08-18 2018-01-16 G-Treebnt Co., Ltd. Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid
US10851097B2 (en) 2015-11-03 2020-12-01 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
PL3371185T3 (pl) 2015-11-03 2021-04-06 Topivert Pharma Limited Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych
AU2017300268B2 (en) * 2016-07-18 2024-06-13 Regentree, Llc Methods of treating dry eye syndrome
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
PT3746429T (pt) 2018-01-30 2022-06-20 Incyte Corp Processos para a preparação de (1-(3-fluoro-2-(trifluorometil)isonicotinoíl)piperidin-4-ona)
CN111670036B (zh) 2018-01-31 2024-08-09 安成生物科技股份有限公司 包含托法替尼的局部调配物
EP4424328A3 (en) 2018-03-30 2024-12-04 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
US12263115B2 (en) 2018-09-11 2025-04-01 Sight Sciences, Inc. Forceps treatment systems
US20220280515A1 (en) * 2019-08-07 2022-09-08 Rohto Pharmaceutical Co., Ltd. Ophthalmic Composition for Promoting Tear Secretion
CN114845734A (zh) * 2019-12-27 2022-08-02 乐敦制药株式会社 水性组合物
CN119367282A (zh) * 2019-12-27 2025-01-28 乐敦制药株式会社 水性组合物
CN111467349B (zh) * 2020-05-14 2021-06-01 华熙生物科技股份有限公司 人工泪液及其制备方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN114948991A (zh) * 2021-02-26 2022-08-30 复旦大学 氢化镁在制备防治干眼病相关眼表炎症药物中的应用
JP2025014078A (ja) * 2021-11-30 2025-01-29 興和株式会社 新規ニコチンアミド化合物及びその用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US5747474A (en) 1996-07-29 1998-05-05 Immune Modulation, Inc. Immunosuppression by administration of N6,N6 -disubstituted cAMP's, analogues thereof, and related nucleosides
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
AU3630100A (en) * 1999-03-19 2000-10-09 Parker Hughes Institute Quinazoline formulations and therapeutic use thereof
JP4078074B2 (ja) 1999-12-10 2008-04-23 ファイザー・プロダクツ・インク ピロロ［２，３−ｄ］ピリミジン化合物
US20020132767A1 (en) * 2000-01-31 2002-09-19 Rosen Craig A. Nucleic acids, proteins, and antibodies
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
TWI324925B (en) * 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
RU2285511C2 (ru) * 2004-10-13 2006-10-20 НИИ ГБ им. Гельмгольца Средство для лечения синдрома сухого глаза
RU2290923C2 (ru) * 2005-03-04 2007-01-10 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Способ лечения синдрома сухого глаза
MX2007012393A (es) * 2005-04-05 2008-02-22 Pharmacopeia Inc Derivados de purina e imidazopiridina para la inmunosupresion.
EP1910358A2 (en) * 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
RU2384583C2 (ru) 2005-07-29 2010-03-20 Пфайзер Продактс Инк. ПИРРОЛО[2,3-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ И СИНТЕЗ
WO2007062459A1 (en) * 2005-11-29 2007-06-07 Cytopia Research Pty Ltd Selective kinase inhibitors based on pyridine scaffold
JP2007314326A (ja) * 2006-05-26 2007-12-06 Mitsubishi Heavy Ind Ltd チョッパ折り方法及び装置
CL2007002867A1 (es) * 2006-10-04 2008-06-27 Pharmacopeia Inc Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras.
JP2010523695A (ja) * 2007-04-11 2010-07-15 アルコン リサーチ， リミテッド アレルギー性鼻炎およびアレルギー性結膜炎を処置するためのＴＮＦαのインヒビターおよび抗ヒスタミン薬の使用
NZ582188A (en) * 2007-07-11 2012-03-30 Pfizer Pharmaceutical compositions and methods of treating dry eye disorders

Also Published As

Publication number Publication date
KR20100029823A (ko) 2010-03-17
EP2175858A1 (en) 2010-04-21
TW200911265A (en) 2009-03-16
CA2691914C (en) 2012-06-26
JP5649270B2 (ja) 2015-01-07
KR101258316B1 (ko) 2013-04-30
RU2009149687A (ru) 2011-07-10
US20130303557A1 (en) 2013-11-14
AU2008273804A1 (en) 2009-01-15
AR067495A1 (es) 2009-10-14
ZA201000991B (en) 2010-12-29
AU2008273804B2 (en) 2014-07-10
ES2523303T3 (es) 2014-11-24
CN101743009A (zh) 2010-06-16
EP2175858B1 (en) 2014-09-10
US20100267751A1 (en) 2010-10-21
TWI364281B (en) 2012-05-21
US8541426B2 (en) 2013-09-24
KR20120115413A (ko) 2012-10-17
CA2691914A1 (en) 2009-01-15
NZ582188A (en) 2012-03-30
JP2009046470A (ja) 2009-03-05
RU2445098C2 (ru) 2012-03-20
WO2009007839A1 (en) 2009-01-15
JP2013147517A (ja) 2013-08-01

Similar Documents

Publication Publication Date Title
BRPI0813553A2 (pt) composições farmacêuticas e métodos para tratamento de distúrbios do olho seco
BRPI0819331A2 (pt) Métodos e composições para o tratamento do olho seco
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
BRPI0719918A2 (pt) Tratamento para olho seco usando-se testosterona e progestagênio
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0916323A2 (pt) composições antimicrobianas de liberação controlada e métodos para o tratamento de distúrbios do ouvido
PT1881823E (pt) Composições e métodos para o tratamento de transtornos oculares
BRPI0918670A2 (pt) composições e métodos para o tratamento de disordens mediados por ige
BRPI0921237A2 (pt) métodos e composições para o tratamento de distúrbios associados ao complemento
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
PT2144998T (pt) Métodos e composições para vírus vivos atenuados
BRPI0819678A2 (pt) método para tratar cmt e distúrbios relacionados
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
BRPI0920326A2 (pt) composição e método para tratamento da síndrome do olho ressecado
BRPI0820980A2 (pt) Composições e métodos para detecção de tiabs
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
BRPI0919804A2 (pt) Métodos e composição para o tratemento de problemas dermatológicos e/ou condições de cabelo
PT2340042E (pt) Métodos e composições para o tratamento de cancro
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BRPI0819105A2 (pt) composição para o tratamento e prevenção de edema de pálpebra
BR112014016389A2 (pt) composições e métodos para o tratamento de doenças e distúrbios hepáticos
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
BRPI0810091A2 (pt) Agentes fugicidas tópicos para tratar distúrbios ungueais

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]